反応式
[CH3:1][N:2]1[C:10]2[C:5](=[N:6][C:7]([C@@H:17]([NH2:19])[CH3:18])=[C:8]([N:11]3[CH2:16][CH2:15][O:14][CH2:13][CH2:12]3)[CH:9]=2)[CH:4]=[CH:3]1.Cl[C:21]1[C:26]([C:27]#[N:28])=[C:25]([CH3:29])[N:24]=[C:23]([S:30][CH3:31])[N:22]=1.CCN(CC)CC>CN(C=O)C>[CH3:29][C:25]1[C:26]([C:27]#[N:28])=[C:21]([NH:19][C@H:17]([C:7]2[N:6]=[C:5]3[CH:4]=[CH:3][N:2]([CH3:1])[C:10]3=[CH:9][C:8]=2[N:11]2[CH2:12][CH2:13][O:14][CH2:15][CH2:16]2)[CH3:18])[N:22]=[C:23]([S:30][CH3:31])[N:24]=1参加物
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
(S)-1-(1-Methyl-6-morpholino-1H-pyrrolo[3,2-b]pyridin-5-yl)ethanamine (100 mg, 0.384 mmol), 4-chloro-6-methyl-2-(methylthio)pyrimidine-5-carbonitrile (77 mg, 0.384 mmol) and Et3N (0.059 mL, 0.423 mmol) in DMF (2 mL) were combined to give a yellow solution. The reaction mixture was stirred overnight at room temperature. The product was purified by LC/MS using a 15-40% CH3CN gradient in H2O with 0.035% formic acid. The pure fractions were combined and lyophilized to afford the title compound as a white solid (109 mg, 67%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.22-1.26 (s, 3 H), 1.50-1.65 (m, 3H), 2.40 (s, 3 H), 2.81-2.91 (m, 2 H), 3.07-3.20 (m, 2 H), 3.74-3.79 (m, 4 H), 3.82 (s, 3H), 5.88-6.00 (m, 1 H), 6.58-6.69 (m, 1 H), 7.76-8.07 (m, 1 H), 7.74-7.78 (m, 1 H), 7.85 (s, 1 H); ESI-MS m/z [M+H]+ calc'd for C21H25N2OS, 424.5; found 424.5.
後処理
- customto give a yellow solution
- customThe product was purified by LC/MS
出典と根拠
- ORDレコード
- ord-346463d456114ffebaaee0e6f421fab3
- 出典データセット
- uspto-grants-2014_09
- 特許番号
- US08835420B2
関連ノート
読み込み中…